𝕽𝖔𝖉𝖓𝖊𝖞 𝕸. 𝕵𝖎𝖒𝖊𝖓𝖊𝖟, 𝕸𝕯

#ACC25 Day 2, here is the summary of today’s trials (I haven’t included the follow-up extensions of Evolut Low Risk, Triluminate, and FAME 3). Today, I counted at least 2 NEJM, 4 Lancet, 1 Nature, 1 JAMA, 1 Circulation, and 1 JACC. 1. MIGHTy-Heart = In-home paramedic visits for heart failure did not reduce 30-day readmissions or improve health status compared to standard follow-up calls. 2. FRESH-UP = Limiting fluid intake showed no benefit for heart failure in the outpatient setting. 3. EQUIOX = Pulse oximeter readings differed significantly between patients with dark and light skin, compared to arterial blood oxygen saturation. 4. FAIR-HF2 = Intravenous iron with ferric carboxymaltose improved quality of life in HFrEF with iron deficiency but did not reduce heart failure hospitalizations or cardiovascular death. 5. BHF PROTECT-TAVI = Cerebral embolic protection during TAVI did not reduce stroke incidence within 72 hours. 6. ALIGN-AR = TAVR with the Trilogy valve in aortic regurgitation showed a 1-year mortality rate of 8.1%, well below the 25% noninferiority goal. 7. FLAVOUR II = AngioFFR, an AI-powered FFR method, was noninferior to IVUS in PCI outcomes for patients with significant stenosis. 8. SMART-CHOICE 3 = Clopidogrel monotherapy was more effective than aspirin in reducing major adverse cardiac and cerebrovascular events after PCI. 9. ALLEPRE = A secondary prevention program with counseling on heart medications and lifestyle changes reduced the primary composite outcome at five years post-ACS. 10. ALPACA = Lepodisiran, an extended-duration, small interfering RNA, reduced lipoprotein(a) concentrations in participants with elevated levels.

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms, and quality of life in PAD with diabetes. API-CAT: Low-dose apixaban was noninferior to full-dose for preventing VTE recurrence in cancer patients. RIVAWAR: Rivaroxaban was as effective and safe as warfarin for post-MI LV thrombus resolution at three months. FARES-II: Four-factor PCC was superior to frozen plasma for bleeding control in cardiac surgery. REVERSE-IT: Bentracimab reversed ticagrelor’s antiplatelet effects in urgent surgery or major bleeding. HOST-BR: Three-month DAPT reduced adverse events without more bleeding vs. one-month in high-bleeding-risk patients post-stent. SOUL: Oral semaglutide reduced MACE by 14% over four years with no safety concerns. ADVANCE-HTN: Lorundrostat significantly lowered systolic BP at 12 weeks in uncontrolled hypertension. DAPA-TAVI: Dapagliflozin reduced mortality and heart failure worsening post-TAVI vs. standard care.